Percutaneous Extracorporeal Ventricular Assist Device as a Successful Bridge Strategy to Durable Left Ventricular Assist Device in Refractory Cardiogenic Shock: A Case Report - Report - MDSpire
Advertisement
Percutaneous Extracorporeal Ventricular Assist Device as a Successful Bridge Strategy to Durable Left Ventricular Assist Device in Refractory Cardiogenic Shock: A Case Report
Clinical Report: Successful Use of a Percutaneous Extracorporeal VAD
Overview
This report details the successful use of a percutaneous extracorporeal ventricular assist device (VAD) as a transitional solution for a patient with refractory cardiogenic shock. The patient improved significantly after 215 hours of support, ultimately leading to durable left ventricular assist device (LVAD) implantation.
Background
Cardiogenic shock (CS) is a critical condition with high mortality rates, necessitating effective temporary mechanical circulatory support (tMCS) strategies. Traditional devices like intra-aortic balloon pumps and ECMO have limitations, highlighting the need for alternative solutions. The use of minimally invasive extracorporeal VADs may provide a viable option for patients who are not candidates for immediate durable LVAD implantation.
Data Highlights
No numerical data or trial data provided in the article.
Key Findings
A 39-year-old male with refractory CS was treated with a percutaneous extracorporeal VAD.
The device was deployed via the right axillary artery and jugular vein without complications.
The patient showed rapid improvement after 215 hours of support.
Subsequently, the patient underwent successful durable LVAD implantation.
This approach effectively alleviated left ventricular load and reduced complications.
Clinical Implications
The use of a percutaneous extracorporeal VAD can serve as a critical bridge for patients experiencing severe cardiogenic shock, particularly in settings where advanced surgical options are limited. This technique may facilitate earlier patient mobilization and streamline postoperative care.
Conclusion
This case underscores the potential of percutaneous extracorporeal VADs as a transitional solution in managing refractory cardiogenic shock, offering a promising alternative to traditional support methods.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
